Tumor gene mutations and messenger RNA expression: Correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer

Chinese Medical Journal

Volumn 124, Issue 1, 2011, Pages 19-25

  Ren, Guan jun ^a   Zhao, Yuan yuan ^a   Zhu, Yu jia ^a   Xiao, Yi ^a   Xu, Jia sen ^b   Shan, Bin ^c   Zhang, Li ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b SurExam Bio Tech Co Ltd   (China)

^c Gleneagles Clinical Research Centre   (China)

Author keywords

Epidermal growth factor receptor; Icotinib hydrochloride; Messenger RNA; Non small cell lung cancer; Somatic mutation

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ICOTINIB HYDROCHLORIDE; K RAS PROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; CROWN ETHER; ICOTINIB; PROTEIN P21; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DNA MICROARRAY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; EXON; GENETICS; MIDDLE AGED; MUTATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CROWN ETHERS; EXONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER;

EID: 79961057151     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.01.005     Document Type: Article

References (24)

1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
2. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-1537.
3. Tan FL, Zhang L, Zhao Q, Liu DY, Hu YY, Liu Y, et al. Pharmacology and clinical evaluation of icotinib hydrochloride. Chin J New Drugs (Chin) 2009; 18: 1691-1694.
4. Dunbar SA. Applications of LuminexR xMAP technology for rapid, high-throughput multiplexed nucleic acid detection. Clin Chim Acta 2006; 363: 71-82.
5. Asano H, Toyooka S, Tokumo M, Ichimura K, Aoe K, Ito S, et al. Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res 2006; 12: 43-48.
6. Flagella M, Bui S, Zheng Z, Nguyen CT, Zhang A, Pastor L, et al. A multiplex branched DNA assay for parallel quantitative gene expression profiling. Anal Biochem 2006; 352: 50-60.
7. Canales RD, Luo Y, Willey JC, Austermiller B, Barbacioru CC, Boysen C, et al. Evaluation of DNA microarray results with quantitative gene expression platforms. Nat Biotechnol 2006; 24: 1115-1122.
8. Yang W, Maqsodi B, Ma Y, Bui S, Crawford KL, McMaster GK, et al. Direct quantification of gene expression in homogenates of formalin-fixed, paraffin-embedded tissues. Biotechniques 2006; 40: 481-486.
9. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
10. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proe Natl Acad Sci USA 2004; 101: 13306-13311.
11. Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005; 11: 1167-1173.
12. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-346.
13. Sasaki H, Endo K, Takada M, Kawahara M, Kitahara N, Tanaka H, et al. EGFR exon 20 insertion mutation in Japanese lung cancer. Lung Cancer 2007; 58: 324-328.
14. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97: 643-655.
15. Kim DW, Lee SH, Lee JS, Lee MA, Kang JH, Kim SY, et al. A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line teatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. (Accessed April 27, 2010 at http://www.elsevier.com/locate/lungcan).
16. Schneider CP, Heigener D, Schott-von-Römer K, Gütz S, Laack E, Digel W, et al. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study. J Thorac Oncol 2008; 3: 1446-1453.
17. Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26: 4268-4275.
18. Wang MZ, Zhang XT, Zhang XY, Zhang L, Zhong W, Xu LY, et al. Efficacy and safety of erlotinib as monotherapy for advanced non-small cell lung cancer. Acta Acad Med Sin 2010; 32: 151-156.
19. Fukuoka M, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N, et al. Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS). Proc Am Soc Clin Oncol 2009; 27 Suppl: a 8006.
20. Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001; 7: 1850-1855.
21. Dziadziuszko R, Witta SE, Cappuzzo F, Park S, Tanaka K, Danenberg PV, et al. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. Clin Cancer Res 2006; 12: 3078-3084.
22. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, et al. Assessment of somatic KRAS mutations as a mechanism associated with resistance to EGFR-targeted agents: A systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008; 9: 962-972.
23. Thelwell N, Millington S, Solinas A, Booth J, Brown T. Mode of action and application of scorpion primers to mutation detection. Nucleic Acids Res 2000; 28: 3752-3761.
24. Wu S, Zhu Z, He J, Luo X, Xu J, Ren-Heidenreich L. A novel mutant-enriched liquidchip technology for the qualitative detection of somatic mutations in KRAS gene from both serum and tissue samples. Clin Chem Lab Med 2010; 48: 1103-1106.